Skip to main content
Unchecking box will stop auto data updates
Delayed Price USD
Today's Change
Volume
Price Quote as of

More stories below advertisement

Non Selective COX Inhibitor - Pipeline Insight, 2019 Featuring Marina Biotech, Pfizer, and LTT Bio-Pharma - ResearchAndMarkets.com

BusinessWire - Fri Feb 22, 7:11AM CST

The "Non Selective COX Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Non Selective COX Inhibitor - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Non Selective COX Inhibitor development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

Provides a snapshot of the therapeutics pipeline activity for Non Selective COX Inhibitor Features the Non Selective COX Inhibitor pipeline across the complete product development cycle including all clinical and non-clinical stages Offers detailed therapeutic product profiles of Non Selective COX Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across Non Selective COX Inhibitor

Reasons to Buy

Establish a comprehensive understanding of the current pipeline scenario across Non Selective COX Inhibitor to formulate effective R&D strategies Assess challenges and opportunities that influence Non Selective COX Inhibitor research & development (R&D) Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage Identify and understand the sought after therapy areas and indications for Non Selective COX Inhibitor Identify the product attributes and use it for target finding, drug repurposing, and precision medicine Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Non Selective COX Inhibitor to enhance and expand business potential and scope Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress

Companies Mentioned

Marina Biotech Pfizer LTT Bio-Pharma

Topics Covered

1. Report Introduction

2. Non Selective COX Inhibitor - Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Non Selective COX Inhibitor

4. Comparative Analysis

5. Non Selective COX Inhibitor Pipeline Products in Clinical Stages

Product Description Research and Development Product Development Activities

6. Non Selective COX Inhibitor Pipeline Products in Non-clinical Stages

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment: Active Products

Pipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

Product Description Research and Development Product Development Activities Reason for dormancy/discontinuation

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/zzxtz8/non_selective_cox?w=4

https://cts.businesswire.com/ct/CT?id=bwnews&sty=20190222005249r1&sid=cmtx6&distro=nx&lang=en

View source version on businesswire.com: https://www.businesswire.com/news/home/20190222005249/en/

SOURCE: Research and Markets

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900Related Topics: Analgesics

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).